Oblimersen

立即咨询

Oblimersen

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

190977-41-4

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

Oblimersen 是一种针对 BCL-2 RNA 的BCL-2抑制剂。Oblimersen 与 BCL-2 mRNA 序列的前六个密码子特异性结合，导致BCL-2 mRNA 降解，并通过下调 BCL-2 的表达诱导细胞凋亡。Oblimersen 可用于癌症研究。

生物活性

Oblimersen is aBCL-2inhibitor targetingBCL-2RNA. Oblimersen specifically binds to the first six codons of thebcl-2mRNA sequence, resulting in degradation ofbcl-2mRNA and inducesapoptosisby down-regulating expression ofBcl-2. Oblimersen can be used forcancerresearch^[1]^[2]^[3].

体外研究
(In Vitro)

Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) decreases BCL-2 protein expression in vitro^[1].
Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) increases radiation-induced apoptosis^[1].

Cell Cycle Analysis^[1]

Cell Line:	Human small-cell lung cancer cell lines H69
Concentration:	500 nM
Incubation Time:	72 hours
Result:	Decreased BCL-2 protein levels.

Cell Cycle Analysis^[1]

Cell Line:	Human small-cell lung cancer cell lines H69
Concentration:	500 nM
Incubation Time:	72 hours
Result:	Arrested cell cycle at sub G1 phase.

体内研究
(In Vivo)

Oblimersen (10 mg/kg; i.p.; daily, for 6 days; nude mice bearing H69 xenografts) decreases tumoural vascularisation in vivo^[1].
Oblimersen (5-10 mg/kg; i.p.; daily (Monday to Friday), for 3 weeks) has antitumor efficacy in the subcutaneous tumor model^[2].

Animal Model:	Male severe combined immunodeficient (SCID)-RAG2 mice^[2]
Dosage:	5 and 10 mg/kg
Administration:	Intraperitoneal injection; daily (Monday to Friday), for 3 weeks
Result:	Inhibited tumor growth in a dose-dependent manner.

Clinical Trial

CAS 号

190977-41-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.